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Molecular mechanism of SbmA, a promiscuous 
transporter exploited by antimicrobial peptides
Dmitry Ghilarov1†, Satomi Inaba-Inoue2,3,4†, Piotr Stepien1†, Feng Qu2,3, Elizabeth Michalczyk1‡, 
Zuzanna Pakosz1,5‡, Norimichi Nomura6, Satoshi Ogasawara6, Graham Charles Walker7, 
Sylvie Rebuffat8, So Iwata6,9,10, Jonathan Gardiner Heddle1*, Konstantinos Beis2,3*
Antibiotic metabolites and antimicrobial peptides mediate competition between bacterial species. Many of them 
hijack inner and outer membrane proteins to enter cells. Sensitivity of enteric bacteria to multiple peptide anti-
biotics is controlled by the single inner membrane protein SbmA. To establish the molecular mechanism of pep-
tide transport by SbmA and related BacA, we determined their cryo–electron microscopy structures at 3.2 and 6 Å 
local resolution, respectively. The structures show a previously unknown fold, defining a new class of secondary 
transporters named SbmA-like peptide transporters. The core domain includes conserved glutamates, which provide 
a pathway for proton translocation, powering transport. The structures show an outward-open conformation with 
a large cavity that can accommodate diverse substrates. We propose a molecular mechanism for antibacterial 
peptide uptake paving the way for creation of narrow-targeted therapeutics.
INTRODUCTION
Bacterial species are under continuous warfare with each other for 
access to nutrients. To gain an advantage in this struggle, they pro-
duce antibacterial compounds that target and kill closely related species. 
Antimicrobial peptides (AMPs), including nonribosomally synthesized 
peptides (NRPs) and ribosomally synthesized posttranslationally 
modified peptides (RiPPs), form a key part of this arsenal, together 
with polyketide natural products acting as antibiotics. Unlike 
membrane-targeting AMPs, many NRPs and RiPPs inhibit key enzymes 
in the cytoplasm, which is essential for cell survival. The Escherichia 
coli inner membrane transporter SbmA (EcSbmA) was found in a 
genetic screen for sensitivity to the azole-modified RiPP antibiotic 
microcin B17 (MccB17) (1) and subsequently was confirmed as the 
most important determinant of sensitivity to several structurally 
unrelated RiPPs from Gram-negative bacteria, including the lasso 
peptide microcin J25 (MccJ25) (2), the azole-modified peptide 
klebsazolicin (KLB) (3), and the NRP-polyketide azole–containing 
antibiotic bleomycin (4). Reliance of all these compounds on a single 
membrane protein for transport is unexpected, given their different 
sizes and chemical structures (Fig. 1A). Besides these compounds, 
SbmA was subsequently found to import a variety of other substrates, 
including the eukaryotic proline-rich AMP Bac7(1-35) (5, 6), and 
peptide nucleic acid–peptide conjugates (7). While the exact natural 
function of EcSbmA is not established, it is a virulence factor in a 
avian pathogenic E. coli (APEC) (8), while its Brucella abortus 
ortholog (BaBacA) is required for chronic intracellular infection in 
a mouse model (9). EcSbmA is isofunctional with BacA from 
Sinorhizobium meliloti (SmBacA), which is critically required for 
the chronic intracellular infection of root nodule cells that underlies 
nitrogen-fixing symbiosis with the legume host by transporting 
nodule-specific defensin-like cysteine-rich peptides (NCRs) (10, 11, 12). 
In summary, peptide internalization by SbmA/BacA is a key com-
ponent of antibiotic sensitivity, legume symbiosis, and virulence 
phenotypes. The closest functional and structural homolog of SbmA 
and BacA is the adenosine triphosphate (ATP)–binding cassette 
(ABC) transporter Rv1819c from Mycobacterium tuberculosis (13), 
but it cannot provide full interchangeable function to the SbmA and 
BacA transporters (14). To establish the molecular mechanism of 
peptide transport and substrate promiscuity of EcSbmA/SmBacA, 
we determined the cryo–electron microscopy (cryo-EM) structure 
of both SbmA and BacA proteins in a lipid bilayer mimetic environ-
ment, using proteins reconstituted in nanodiscs (NDs), at 3.2 and 
6 Å local resolution, respectively.
RESULTS
Because of the small size of SbmA (45-kDa monomer), we raised 
antibodies against it to increase its size and facilitate structure de-
termination (fig. S1). One Fab showed a monodisperse peak after 
purification (designated Fab-S11-1). SbmA-Fab-S11-1 was recon-
stituted in membrane-scaffold protein 1 D1 (MSP1D1) NDs com-
posed of palmitoleoyl-oleoyl phosphatidylethanolamine (POPE), 
palmitoleoyl-oleoyl phosphatidylglycerol (POPG), and cardiolipin 
(CL), in a ratio of 7:2:1, to mimic the E. coli bilayer composition (fig. 
S2). To show that reconstitution into NDs did not alter the function 
of SbmA, we performed ligand binding studies by microscale thermo-
phoresis (MST), demonstrating that SbmA can bind MccB17, bleo-
mycin, and KLB with the dissociation constant (Kd) of 428 ± 89 nM, 
88 ± 14 nM, and 849 ± 196 nM, respectively (Fig. 1B). A twofold 
symmetrical SbmA-Fab complex, with a characteristic “bunny ears” 
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Fig. 1. Structural characterization of SbmA. (A) Antibiotic peptide substrates of SbmA. Azoles in MccB17 and KLB are labeled in red; lactamidine and piperidine in KLB 
and bleomycin, respectively, are in blue; MccJ25 is a cyclic peptide closed by an isopeptide bond (in red) having a threaded topology. Bleomycin sulfate used in this study 
is a mixture of related compounds containing different C-terminal groups (R). (B) MST curves showing binding of MccB17, bleomycin, and KLB to the ND-embedded 
SbmA. (C) EM map of SbmA-FabS11-1-ND complex. Two maps contoured at different levels are overlaid to represent both high-resolution (SbmA) and low-resolution 
(ND) parts. (D) Tube diagram for SbmA. TM helices mentioned in the text are shown. (E) A slice through SbmA showing the internal cavity and constriction near Tyr368. 
Cavity dimensions are indicated. (F) A ribbon diagram showing bound PG lipid (stick representation) and gates mentioned in the text. (G) Surface representation of SbmA 
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appearance, was immediately obvious in electron micrographs and 
two-dimensional (2D) class averages (fig. S3), which agrees with our 
previous study showing that SbmA exists as a homodimer (15). We 
obtained a 3D reconstruction initially at 3.74 Å global resolution for 
SbmA-Fab-S11-1-ND, which was subsequently improved to 3.6 Å 
for the SbmA-Fab-S11-1-MccB17 dataset (see below); the local res-
olution for SbmA was estimated as 3.2 Å, allowing identification of 
side chains (Fig. 1A and fig. S3). Continuous Coulomb potential 
density could be observed for both the SbmA and Fab S11-1, which 
allowed us to build its de novo structure from residues 1 to 391 (Fig. 1B); 
no density could be observed for the last 25 residues. Density for the 
MSP1D1 ND forming a tight belt around the protein was also ap-
parent, defining the section of the protein embedded in the mem-
brane (Fig. 1B). Given the partial flexibility of the Fab fragments 
(local resolution <6 Å), they have been placed only as rigid mole-
cules and not refined.
SbmA is a homodimer consisting of eight transmembrane (TM) 
helices per protomer. SbmA consists of two TM0 domains and a 
core TM domain (TMD), which comprises 12 TM helices; we des-
ignated the first two TMs of the TM0 domain as TMs 0a and 0b and 
the core of the transporter as TMs 1 to 6 (Fig. 1D). The overall struc-
ture of TMD notably resembles the TMD of ABC transporters (ex-
porters), such as MsbA (lipid A flippase) (16) from E. coli, Sav1866 
(multidrug resistance) from Staphylococcus aureus (17), and Rv1819c 
(cobalamin transporter) from M. tuberculosis (fig. S4) (13). Despite 
these similarities, the structural organization of SbmA has not been 
observed in secondary transporters before; ABC transporter fold 
refers to full-length ABC transporters containing a nucleotide bind-
ing domain (NBD). Therefore, SbmA defines a new fold for secondary 
transporters, which we named SbmA-like peptide transporter (SLiPT) 
fold. Rv1819c also contains an additional extended TM helix 0 that 
interacts with TMs 1 and 2 forming a cap at the periplasmic side of 
the TMD (13), but its overall structure does not display any similar-
ity with the TM0 of SbmA (fig. S4). The SbmA dimer interface is 
formed between TMs 1 and 2 and 5 and 6 from one protomer and 
the equivalent ones from the second; TMs 1 and 2 form intermolecular 
contacts with TMs 5′ and 6′, and TMs 5 and 6 form intermolecular 
contacts with TMs 1′ and 2′. The TM0 domain of SbmA is a novel 
feature of SLiPT transporters, which is not present in any other 
known transporter structure; TMs 0a and 0b do not participate in 
the dimer formation, and they do not extend beyond the lipid inter-
face. The core domain spans the bilayer and reaches out into both 
the periplasmic and cytoplasmic space. In our structure, a phospha-
tidyl glycerol (PG) lipid is found in the interface of TMs 0a/0b and 
TM1, suggesting a possible role in either transporter conformational 
changes or stability in the membrane (fig. S5, S10). We have previ-
ously shown that PG lipids are important for the transport activity 
of the MccJ25 ABC exporter McjD (18), whereas PE lipids were im-
portant for its structural integrity. Therefore, it is likely that the bound 
PG facilitates substrate transport. SbmA is trapped in an outward- 
open conformation that more closely resembles the overall confor-
mation of the nucleotide-bound outward-open MsbA (16) and 
Sav1866 (17) structures than the nucleotide-bound outward-occluded 
Rv1819c; SbmA and the TMD of Sav1866 and Rv1819c can be su-
perimposed with a root mean square deviation of 3.4 and 3.5 Å, re-
spectively, over 350 C atoms (fig. S4). Another notable feature of 
SbmA is the absence of the two coupling helices between TMs 2 and 
3 and TMs 4 and 5, which are important for transmitting conforma-
tional changes between the NBDs and the TMD of ABC exporters 
(fig. S4). In SbmA, TMs 2 and 3 and TMs 4 and 5 are linked by short 
loops without any secondary structure. In the TMD, TMs 4 and 
5 display a kink in their midpoint in the membrane, whereas TMs 6 
are “broken” helices (we refer to them as TMs 6a and 6b) defin-
ing an hourglass-shaped funnel (fig. S6), suggesting flexibility 
and a possible role in conformational changes associated with the 
transport cycle. Similar broken helices have been reported for the 
Rv1819c and secondary transporters, for example, the leucine trans-
porter LeuT from Aquifex aeolicus, where it has been shown to be 
important for its transition from outward- to inward-facing confor-
mation (19). In its outward-open conformation, SbmA displays a 
large cavity open on the periplasmic side, where the peptides can 
bind and be transported to the cytoplasm (Fig. 1E). However, the 
cavity is open only halfway; the first internal gate formed by Tyr368 
and Tyr368′ at the bottom of TM 6a constricts it at the midpoint 
between the periplasm and the inner membrane (Fig. 1, E and F). 
Two further gates are present, which seal the TMD at the cyto-
plasmic side of the membrane: a cytoplasmic gate, formed by Tyr285 
and Asp288′, and a second internal gate between Arg280 and Arg280′ 
(Fig. 1F). The open cavity that SbmA displays is of sufficient size to 
accommodate the diverse peptides that it transports. A similar sized 
cavity is seen in the ABC exporter McjD, where one MccJ25 peptide 
can fit and be transported (20, 21). The electrostatic map of SbmA 
(Fig.  1G) shows clear negative (top) and positive (bottom) belts 
around the surface, which could facilitate top-to-bottom transport 
of positively charged ions by binding them from the surface of the 
membrane.
Since SbmA adopts a novel fold, we wanted to exclude the possi-
bility that the Fabs or unusually tight encirclement by MSP1D1 
induced structural changes. Therefore, we determined the structure 
of SbmA in the absence of Fabs in larger MSP1E3D1 NDs, which 
contained more unsaturated lipids [dioleoyl phosphatidyletha-
nolamine (DOPE):POPG:CL; 13:4:1] to increase membrane fluidity 
(fig. S7). The ~3.8-Å reconstructions display the same overall fold 
as the SbmA-FabS11-1 complex, suggesting that neither the Fab 
nor the size and fluidity of the ND influence the conformation of 
SbmA. Considering the important biological role of BacA in symbi-
osis, it is important to show that the insights gained from the SbmA 
structure can be used to interpret the BacA action, especially as the 
EcSbmA is isofunctional with the SmBacA. As we were able to ob-
tain a 3.9-Å reconstruction of the Fab-free SbmA, we also de-
termined the low-resolution structure of BacA from S. meliloti to 
probe whether it has a similar fold; the two proteins share ~64% 
sequence identity (fig. S10). The BacA reconstruction displays the 
same overall fold as SbmA, in either small or large NDs, but because 
of resolution limitations, we have not built or refined its structure in 
the reconstructions (Fig. 2A and fig. S8). The functional activity of 
reconstituted BacA was tested in MST assays, showing that the BacA-ND 
complex binds bleomycin and MccB17 with a Kd of 19 ± 11 nM and 
31 ± 22 nM, respectively (Fig. 2B). The SbmA structure can fit in the 
BacA map without any structural changes, including the TM0 do-
main, suggesting that BacA also adopts an outward-open confor-
mation. The BacA structure provides further evidence that SbmA 
and BacA define a new class of secondary transporters conserved 
among different bacterial species. Our attempts to capture bleomy-
cin, MccJ25, or MccB17 peptides bound to SbmA or BacA did not 
yield any density for them; however, the dataset collected in the 
presence of MccB17 was chosen as the highest resolution one and 
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We have previously shown that SbmA is a proton-driven trans-
porter in E. coli cell assays (15). To probe the mechanism of proton 
translocation, we reconstituted SbmA and BacA in liposomes con-
sisting of POPE:POPG (3:1) (fig. S9). Using the pyranine assay (Fig. 2C), 
we demonstrated that transport can only be initiated in the pres-
ence of both a proton gradient (induced by valinomycin) and the 
substrates bleomycin or MccB17 (Fig. 2, D and E, and fig. S9). Be-
tween the internal gate defined by Tyr368 and the cytoplasmic gate 
defined by Tyr285 and Asp288′, the SbmA cavity is lined with conserved 
Glu residues, forming a “glutamate ladder,” suggesting a relay path 
for proton movement (Fig. 3A and figs. S5 and S10). To probe their 
role in coordinating proton translocation, we mutated the glutamates 
to alanines and measured their substrate transport activity (Fig. 3B). 
All Glu-to-Ala mutations essentially abolished substrate transport, 
consistent with our previous reports. Since the transport assay 
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Fig. 2. Structure of BacA and functional characterization of SbmA and BacA. (A) Structure of SbmA fitted into the low-resolution EM map of BacA-ND showing fold 
conservation. (B). Activity of reconstituted BacA demonstrated by the binding of substrates measured by MST. (C) A schematic of transport assay. Addition of valinomycin 
creates efflux of potassium cations out of the liposome, resulting in a charge gradient across the membrane. In the presence of the substrate peptide, SbmA allows the 
protons to travel down the gradient, resulting in a decreased internal pH measured by pyranine fluorescence. (D) The transport data for SbmA in the presence of bleomy-
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fluorescence quenching, we performed growth inhibition and lawn-
spot assays in E. coli sbmA cells complemented with either wild-type 
(WT) SbmA or Glu mutants. We evaluated these mutants under 
two different conditions, low- and high-protein expression. Under 
low-protein expression conditions (mimicking the low abundance 
of protein in proteoliposomes), all the mutants made cells resistant 
to bleomycin, MccB17, KLB, and MccJ25 at the level of the parent 
sbmA strain, providing further evidence on the role of the gluta-
mates in proton-mediated substrate translocation (Fig. 3D and figs. 
S11 and S12). Under high-protein expression (preinduction of starter 
culture), the cells that carry the Glu193Ala and Glu378Ala mutants 
become sensitive to some antibacterial peptides, suggesting that while 
some proton translocation can still occur, the transporter is sub-
stantially slowed down because of either inefficient proton movement 
or possible disruption of required conformational changes. Thus, the 
high-protein expression assays allow us to distinguish between 
mutants with severely affected transport and those that have truly 
lost their transport capability. The structure and functional data 
suggest that the funnel-shaped central part of the TMD, as defined 
by TMs 6a and 6b from both protomers, can guide protons toward 
the glutamate ladder, which facilitates their movement.
Disruption of the second internal (Arg280Ala) and cytoplasmic 
(Tyr285Ala) gates also affects substrate transport, conferring cells 
with complete or almost complete resistance to all SbmA substrate 
antibiotics tested (Fig. 3D). Although it appears that the first inter-
nal gate, Tyr368/Tyr368′, is protecting the glutamate ladder by pre-
venting proton dissociation, the Tyr368Ala mutant not only remains 
sensitive to all peptides but also appears to be additionally sensitized 
to bleomycin, suggesting that this residue defines the boundary of 
the peptide-binding part of the cavity (the substrates sitting above 
this gate). In the absence of a peptide-bound structure, we also mu-
tated some of the conserved arginines and lysines lining the cavity 
of SbmA (Lys281, Arg190, and Arg385). Although they are forming 
salt bridges with the conserved glutamates, we could not exclude their 
role in substrate binding. All these mutants provide cells with com-
plete or nearly complete resistance to all substrate peptides with the 
exception of Arg385 whose side chain points away from the cavity 
(Fig. 3D). We further hypothesized that Tyr116 may participate in 
periplasmic gate formation upon peptide transport (Fig. 3, C and D). 
Mutation of this residue, similar to Tyr368, slightly increased sensi-
tivity to bleomycin and notably made cells resistant to MccB17, KLB, 
and MccJ25. We propose that this residue might act as an anchor 
for initial binding of microcin peptides; in particular, in the case of 
MccB17 and KLB, the side chain of Tyr116 might stack against the 
azole, similar to what was observed in the case of LAPs and the ri-
bosome (22). The DNA gyrase residue implicated in MccB17 bind-
ing is also an aromatic residue, GyrB Trp751, suggesting a further 
role in MccB17 recognition (23). Together, this work establishes a 
previously unknown proton-driven secondary transporter fold as 
defined by the SbmA and BacA structures, which we believe should 
be referred to in the literature as “SbmA-like peptide transporters 
(SLiPT) fold” as homologs of the EcSbmA and SmBacA proteins are 
very likely to adopt the same overall fold.
SLiPT transporter mechanism
Our data allow us to suggest a mechanism for antibacterial peptide 
import by SbmA and BacA proteins (Fig. 4), reminiscent of ABC 
transporters. In its resting state (Fig. 4I), SbmA adopts an outward- 
open conformation with its cavity accessible to both peptide and 
proton. Binding of a proton in Glu203, with subsequent movement 
along the glutamate ladder, and simultaneous peptide binding in 
the open cavity induce either a transient or a stable occluded state, 
similar to the ABC transporters McjD (20, 21) or Rv1819c (13); this 
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Fig. 3. Structure-functional analysis of SbmA. (A) A cartoon representation of SbmA and glutamates, forming the glutamate ladder. (B) Transport assay data for the 
glutamate mutants. (C) A cartoon representation of SbmA showing Y116 (potential periplasmic gate) residue. (D) Antibiotic sensitivity of SbmA mutants upon conditions 
of low and high expression. Green: The mutation has no effect on transport, sensitive cells. Red: Cells become fully resistant at the level of SbmA strain. Yellow: Resistant 
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toward TMs 5′ and 6′ (Fig. 4, IV). An inward-facing open conformation 
can be formed by opening the cytoplasmic gate and movement of 
TMs 4 and 5 away from TMs 4′ and 5′; our growth assays suggest 
that disruption of the internal gate affects transport. Notably, all fully 
resistant mutants are found along TM5, suggesting its important role 
in substrate translocation associated with conformational changes 
along the transport cycle; the broken TM6, as observed in both SbmA 
and Rv1819c, can possibly facilitate this conformational change. In 
the inward-open conformation, the antibacterial peptide and pro-
ton are released in the cytoplasm, and the transporter resets in the 
outward-open conformation. A high degree of coupling, observed 
in our transport assays, suggests that proton and peptide translocation 
can only occur in the presence of both since they can induce the 
required structural rearrangements.
DISCUSSION
Although SbmA/BacA structurally resemble the TMD of ABC ex-
porters, they are not energized by ATP as established by our func-
tional data in proteoliposomes, growth curves, and lawn assays. We 
have previously shown in pull-down and bacterial two-hybrid assays 
the absence of any orphan NBDs that could bind to SbmA (15). In 
this study, our structures clearly demonstrate that SLiPT transporters 
lack the coupling helices that would be necessary for any orphan 
NBDs to bind and energize them (fig. S4). It has previously been 
shown that the ABC transporter LmrA, devoid of its NBD, can be 
energized by the proton gradient (24), although no glutamate lad-
der is present that could provide a clear path for proton movement. 
This observation, together with our structural and functional data, 
suggests an evolutionary link between full-length ABC transporters 
and SLiPTs. The possibility that the proton-driven SLiPTs may have 
coevolved together with or from full-length ABC transporters is fur-
ther supported by the substrate promiscuity observed in SbmA and 
BacA transporters.
If cells can defend themselves against AMPs that kill predomi-
nantly by membrane permeabilization by importing them into the 
cytoplasm for degradation (e.g., 25), the loss of the transporter sen-
sitizes the bacteria to the peptide and reduces their virulence. Since 
loss of SbmA in an avian E. coli reduces its virulence (8), while loss 
of BacA in B. abortus and S. meliloti reduces their virulence in 
mouse and symbiotic proficiency, respectively, it seems likely that 
AMP import by SbmA/BacA may underlie its importance for inter-
actions with eukaryotic hosts. In this logic, internalized antibiotics 
used in this study hijack SbmA/BacA to reach the cytoplasm. In the 
case of Rhizobium-legume symbioses, importing plant NCR pep-
tides into the cytoplasm via BacA not only limits killing from mem-
brane disruption (12) but also ensures that the NCR peptides are 
able to make necessary interactions with their intracellular bacterial 
targets to force terminal differentiation into nitrogen-fixing bacte-
roids. The Rhizobium-specific RiPP phazolicin was recently described 
(22), which is structurally similar to MccB17 and KLB. It is not 
known how phazolicin enters Rhizobium cells, but it is likely that 
the BacA protein would be involved. Thus, we believe that SbmA- 
targeting molecules provide an important avenue for the develop-
ment of novel selective antibacterials that can cross the inner 
membrane of Gram-negative pathogens by hijacking the SbmA 
transporter for internalization.
MATERIALS AND METHODS
Purification of SbmA and BacA
SbmA from E. coli and BacA from S. meliloti were overexpressed in 
E. coli C43 (DE3) or Lemo21 (DE3) and purified in 20 mM tris (pH 8.0), 
150 mM NaCl, and 0.03% n-Dodecyl -D-maltoside (DDM) as pre-
viously described without modifications (fig. S1) (15).
Generation of anti-SbmA antibodies
All the animal experiments conformed to the guidelines of the Guide 
for the Care and Use of Laboratory Animals of Japan and were ap-
proved by the Kyoto University Animal Experimentation Committee. 
Mouse monoclonal antibodies against SbmA were raised according 
to the previously described method (26). Briefly, a proteoliposome 
antigen was prepared by reconstituting purified, functional SbmA 
at high density into phospholipid vesicles consisting of a 10:1 mix-
ture of egg phosphatidylcholine (Avanti Polar Lipids) and the adju-
vant lipid A (Sigma-Aldrich). BALB/c mice were immunized with 
the proteoliposome antigen using three injections at 2-week inter-
vals. Antibody-producing hybridoma cell lines were generated us-
ing a conventional fusion protocol. Hybridoma clones producing 
antibodies recognizing conformational epitopes in SbmA were se-
lected by an enzyme-linked immunosorbent assay on immobilized 
phospholipid vesicles containing purified SbmA, allowing positive 
selection of the antibodies that recognized the native conformation 
of SbmA. Additional screening for reduced antibody binding to 
SDS-denatured SbmA was used for negative selection against linear 
epitope–recognizing antibodies. Stable complex formation between 
SbmA and each antibody clone was checked using fluorescence- 



















Fig. 4. Proposed mechanism for SbmA peptide transport. (I) Proton is free to bind 
when the transporter is in the outward-open state, but proton transport is precluded. 
Inner cavity is occluded by Tyr368. Glu203 is essential for transport and is marked as 
a potential first proton-binding site (II). (III) Binding of substrate peptide (Tyr116 is 
essential for MccB17 and MccJ25) triggers conformational changes, resulting in a 
transient or stable occluded state (IV). (V) Structural rearrangements result in an 
inward-open conformation and subsequent release of the proton into the cyto-
plasm, using the glutamate ladder, leading to the dissociation of the peptide; the 
transporter resets in its outward-open conformation. Only one copy of the gluta-
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from the antibody clone number S11-1 was determined via standard 
5′-RACE using total RNA isolated from hybridoma cells.
Preparation of the SbmA-fab complex for cryo-EM
For the generation of the SbmA-Fab complex for structural studies, 
monoclonal antibody S11-1 was digested and purified using the Pierce 
Fab Preparation Kit. The purified Fab S11-1 was dialyzed in 20 mM 
tris (pH 7.5) including 25 mM NaCl. The SbmA and Fab S11-1 were 
mixed in a 1:2 molar ratio, and excess Fab was separated from the 
SbmA-Fab complex by size-exclusion chromatography using a 
Superdex S200 column (Cytiva) in 20 mM tris-Cl (pH 8.0), 150 mM 
NaCl, and 0.03% DDM.
ND incorporation
Plasmids for expression of MSP1D1 and MSP1E3D1 were a gift from 
S. Sligar (Addgene plasmid nos. 20061 and 20066) (27). The double 
cysteine mutation in MSP1E3D1 (S22C and A121C) was introduced 
using two steps of site-directed mutagenesis polymerase chain reac-
tions. SLiPT discs containing SbmA and BacA were prepared as fol-
lows: Briefly, 20 mol of desired lipid mixture was dried using gentle 
argon stream and subsequently placed in vacuum for at least 2 hours 
to remove residual chloroform. Next, the film was hydrated with 
20 mM tris-Cl (pH 7.5) and 150 mM NaCl buffer and sonicated to 
prepare small unilamellar liposomes. Those were subsequently sol-
ubilized using DDM to yield a clear solution with a final concentra-
tion of 7.5 mM for lipids and 33 mM for DDM. Purified SbmA or 
BacA (7.7 to 21.3 mg ml−1) was added to lipid/detergent micelles and 
incubated at 28°C for 30 min. Next, the membrane scaffold protein 
was added, followed by 5 min of incubation, addition of Amberlite 
XAD-2 (80 mg of damp beads per 1 mg of detergent), and overnight 
incubation at 28°C. The following day, the NDs were purified using 
Superdex 200 Increase 10/300 (Cytiva) equilibrated with cryo-EM 
buffer [K-Hepes 20 mM (pH 7.5) and KCl 120 mM]. The mem-
brane protein:MSP:lipid ratios for both membrane proteins were 
1:2:100 for MSP1E3D1 and 1:2:50 for MSP1D1. Lipid mixtures used 
for MSP1E3D1 and MSP1D1 were 13:4:1 of DOPE/POPG/POPOCL 
and 14:4:2 of POPE/POPG/POPOCL, respectively. The samples were 
then concentrated using 50-kDa centrifugal concentrators (Millipore) 
to a concentration of 6 to 9 mg/ml total protein and immediately 
used for grid preparation.
For a dataset with MccB17, purified MccB17 was added at 100 M 
concentration, and the sample was incubated at 37°C for 1 hour. 
Fluorinated octyl maltoside, a nonsolubilizing detergent, was added 
at 0.05% to improve particle distribution in ice and to limit the ag-
gregation of MccB17.
Microscale thermophoresis
For MST studies, MSP1E3D1 (S22C and A121C) was labeled using 
Alexa Fluor 647 C2 maleimide (Thermo Fisher Scientific). Briefly, 
10 eq. of the maleimide dye dissolved in dimethyl sulfoxide (DMSO) 
was added to 1 eq. of MSP1E3D1 (S22C and A121C) reduced with 
2 mM tris(2-carboxyethyl)phosphine (TCEP), and incubated for 
2 hours at room temperature in 25 mM K-Hepes (pH 7.2) and 
400 mM KCl. The labeled protein was purified from the excess dye 
and residual DMSO using Superdex 200 Increase 10/300 and used 
in the ND formation protocol described above. The labeling effi-
ciency was measured by the 280- and 650-nm absorbance of the 
final protein product, and the typical yield was in the range of 1.65- to 
1.8-labeled cysteines per MSP1E3D1 (S22C and A121C).
MST experiments were performed using a Monolith NT.115 
(NanoTemper) instrument using a red filter set. SbmA-containing 
Alexa Fluor 647–labeled NDs [20 nM in 20 mM K-Hepes (pH 8) 
and 150 mM KCl] were mixed with bleomycin, KLB, and MccB17 
(the last two were dissolved in DMSO; the final DMSO concentra-
tion in the reaction was 1.25%) and incubated in MST buffer [20 mM 
K-Hepes (pH 8), 150 mM KCl, and 0.005% Tween 20] in the dark 
for 15 min.
Fluorescence signal was measured using MO.Control software 
(Nanotemper) in Monolith NT.115 Premium Capillaries (#MO-K025). 
MST signal was used for binding analysis in MO.Affinity software 
(Nanotemper) using 1:1 binding mode. The Kd values were calcu-
lated on the basis of three independent measurements. All experi-
ments were performed at room temperature.
Electron microscopy
Aliquots of 4 l of ND-embedded complexes (~3 to 5 mg/ml) were 
applied to glow-discharged Quantifoil holey carbon grids (R1.2/1.3, 
300 mesh). After 30 s of incubation with 95% chamber humidity at 
10°C, the grids were blotted for 6 s and plunge-frozen in liquid ethane 
using a Vitrobot mark IV (FEI).
Cryo-EM data were collected at the Polish national cryo-EM 
facility SOLARIS or eBIC (DLS, UK for BacA-free dataset) with a 
Titan Krios G3i microscope (Thermo Fisher Scientific) operated at 
300 kV, and images were collected at a nominal magnification 
of ×105,000 resulting in a calibrated physical pixel size of 0.86 Å per 
pixel with a defocus range of −3 to −0.9 m. The images were re-
corded in counting mode on a K3 electron direct detector (Gatan) 
equipped with GIF BIO Quantum energy filter operated with a slit 
width of 20 eV. A dose rate of 15 electrons per pixel per second was 
used, and exposure time was set to generate a total dose of ∼40 elec-
trons/Å2 over 40 movie frames. Statistics for cryo-EM data collec-
tion are listed in table S1.
Data processing
For the SbmA-Fab dataset, 5421 movies were imported to cryoSPARC 
v2.15 for patch motion and contrast transfer function (CTF) correc-
tion (28). A total of 2000 particles were manually picked to train a 
Topaz model (29), used initially to pick 100 micrographs. Another 
round of Topaz training was performed, using cleaned-up particles 
from this small subset. This improved model was applied to the whole 
dataset, yielding 1,236,218 particles. After rounds of 2D classification 
in cryoSPARC, an initial model was produced with a global resolu-
tion of ~4.2 Å. This model was used to create templates used for 
particle picking during the final round of processing (fig. S3). In this 
final round, template-picking resulted in 1,182,621 particles, which 
were extracted with a pixel size of 1.72 Å per pixel and cleaned up in 
multiple rounds of 2D classification. Ab initio procedure in cryoSPARC 
was used for further cleaning of particle stack. Iterative rounds of 
cryoSPARC nonuniform refinement (30) with C2 symmetry imposed, 
followed by reextraction of full-size particles, local motion (31), and 
CTF correction (32), yielded a final map with a global resolution of 
3.74 Å from 320,796 particles. For the processing of SbmA-Fab-MccB17 
data, initial analysis using Topaz-picked particles showed that the 
structures are indistinguishable from SbmA-Fab. Therefore, tem-
plates from the latter model were used for picking, resulting in 
407,426 particles from 7286 micrographs. After particle cleaning by 
2D classification and ab initio 3D classification, particles were reex-
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in a final 3.59-Å map from 116,545 particles after cryoSPARC non- 
uniform refinement. The local resolution for SbmA protein was esti-
mated by cryoSPARC to lie between 3.1 and 3.4 Å. This map was 
postprocessed by DeepEMhancer (33), which further improved con-
nectivity and was used for model building and refinement.
SbmA without Fabs dataset was processed in a similar way (fig. S7). 
Templates were prepared after initial Topaz picking, and template- 
based picking of 6881 micrographs resulted in 2,060,359 particles. 
The 2 × 2 binned particles (1.72 Å per pixel) were subjected to mul-
tiple rounds of 2D classification in cryoSPARC to remove empty 
NDs and contamination classes. The resulting stack of 298,548 par-
ticles was used to produce ab initio model in cryoSPARC; however, 
ab initio classification failed to separate high-resolution particles. 
Therefore, particles were imported to RELION 3.1 (34) using pyem 
script (35) and subjected to unsupervised 3D classification with no 
symmetry imposed and soft mask over the whole particle. One of four 
classes (63,291 particles) was found to display clear transmembrane 
helices; this class was imported back to cryoSPARC, and after ex-
traction of full-size (0.86 Å per pixel) particles, subjected to nonuni-
form refinement with local CTF correction. The final map derived 
from 62,372 particles had a global resolution of 4.06 Å as estimated 
by cryoSPARC.
For the BacA-free dataset, 405,208 particles were picked from 
2980 micrographs using the Topaz model trained on a small manu-
ally picked subset. After multiple rounds of cryoSPARC 2D classifi-
cation, class averages with clear protein features (105,059 particles) 
were selected. Ab initio classification showed that two populations 
of NDs are present, one being slightly larger than the other (~100 
and ~110 Å diameter). Both subsets of particles were imported to 
RELION 3.1 and subjected to unsupervised 3D classification. For 
the final reported map, 17,648 particles with clear density for TM 
helices were selected from a small ND class and imported back to 
cryoSPARC v3.2 for non-uniform refinement with adaptive margin-
alization, resulting in a global resolution of 6.36 Å as estimated by 
cryoSPARC.
SbmA model building and refinement
In the absence of a suitable homologous structure, we built the de 
novo structure of SbmA. An initial model was generated by Buccaneer 
under the collaborative computational project for electron cryo- 
microscopy (CCP-EM) suite using C2 symmetry and further refined 
in Phenix using real-space refinement (36). Most of the helices and 
side chains were placed within the density. Further manual building 
with addition of missing residues was performed in Coot (37) with 
secondary structure restraints to constrain the geometry of the heli-
ces. The ~3.2-Å resolution of the SbmA allowed us to build all miss-
ing helices and to also correct the register of the Buccaneer model 
and generate a final structure that comprises residues 1 to 391; there 
was no density to build the last 15 residues. Clear density for a PG 
molecule was also present and was manually placed in Coot. Further 
improvement of the overall geometry was facilitated by ISOLDE 
(38) in ChimeraX (39). Since the local resolution for the Fab S11-1 
was worse than 6 Å, we could not build its de novo structure or re-
fine it. The closest structural homolog to Fab S11-1 is the antitumor 
antibody A5B7 with Protein Data Bank (PDB) ID 1CLO (40); most 
sequence differences are at the complementarity-determining re-
gion loops. The sequence of the Fab S11-1 was matched onto the 
A5B7 and placed by molecular replacement using Molrep (41) un-
der the CCP-EM suite (42, 43). The placed Fab was then rigid-body 
refined. The final SbmA model was refined with C2 symmetry in 
Phenix using real-space refinement (36). The Ramachandran plot 
does not show any outliers. The model refinement and validation 
statistics are shown in table S1.
Model validation
The structural model of SbmA protein was validated using MolProbity 
(44). Cross-validation to check the possibility of overfitting and the 
predictive power of the model was performed using a half-map val-
idation approach (45). Briefly, the atom positions of the final model 
were randomly displaced by 0.5 Å. Then, refinement against half of 
data from the final map reconstruction is performed using the same 
parameters used to obtain the final model. An EM map was created 
from the refined model using ChimeraX molmap plugin, with the 
Fourier shell correlation (FSC) = 0.143 resolution (3.6 Å) as a filter-
ing threshold. The FSC was then calculated for both the half-map 
against which it had been refined and the map from the other half 
of the data, up to a resolution of 2 Å (FSCwork and FSCtest). Signif-
icant correlation was observed (t test for Pearson correlation r = 0.79 
P = 4.99 × 10−5) beyond the resolution used for refinement up to 
3 Å, demonstrating predictive power for the model and absence of 
over-fitting.
Transport assay
SbmA and BacA proteins for functional assays were reconstituted 
in liposomes using the rapid dilution method. POPE/POPG lipids 
(Avanti Polar Lipids) were mixed in a 3:1 ratio, and chloroform was 
removed by nitrogen gas. The POPE/POPG mixture forms tight li-
posomes without proton leakage. The dried lipid film was resuspended 
in MilliQ water in a final concentration of 20 mg/ml and sonicated 
in a water bath until the solution became less hazy. The liposomes 
were destabilized by the addition of 1.0% DDM. SbmA WT, gluta-
mate mutants (E193A, E203A, E276A, E287A, and E378A), and BacA 
(1.0 mg/ml) were mixed in a 1:4 ratio (protein:lipid) with 300 l of 
lipid vesicles and were incubated on ice for 30 min. The protein- 
liposome mixture was rapidly diluted into 60 ml of reconstitution 
buffer [5 mM K-Hepes (pH 6.8), 120 mM KCl, and 2 mM MgSO4], 
and proteoliposomes were harvested by ultracentrifugation (~200,000g) 
for 2 hours. The pelleted liposomes were resuspended in reconstitu-
tion buffer, and their concentration was determined using a bicin-
choninic acid (BCA) kit (Pierce) and dialyzed against 2 liters of 
reconstitution buffer overnight to remove any remaining detergent. 
Reconstitution efficiency was also determined by analyzing the pro-
teoliposomes by SDS–polyacrylamide gel electrophoresis (fig. S9).
The proteoliposomes were subjected to three rounds of freeze-
thaw in liquid nitrogen and harvested by ultracentrifugation (100,000g) 
for 30 min. The pelleted proteoliposomes were resuspended in in-
side buffer [5 mM K-Hepes (pH 6.8), 1 mM pyranine (trisodium 
8-hydroxypyrene-1,3,6-trisulfonate), 120 mM KCl, and 2 mM MgSO4] 
and subjected to three rounds of freeze-thaw in liquid nitrogen. The 
proteoliposomes were harvested by ultracentrifugation (100,000g) 
for 30 min, and the pellets were washed to remove any free pyranine 
and resuspended in reconstitution buffer. For the transport assay, 
liposomes at a final concentration of 15 M were placed in a cuvette 
and quickly mixed with 1.0 ml of outside buffer [5 mM K-Hepes 
(pH 6.8), 1.2 mM KCl, and 2 mM MgSO4] containing bleomycin 
(100 M) or MccB17 (30 M) with or without valinomycin (1 M). 
To assess that the proteoliposomes are tight and do not leak pro-
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MES-Cl (pH 6.0) and 1.2 mM KCl], and their fluorescence was mea-
sured; no apparent change was detectable. Data were recorded using a 
Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies) 
at the following settings: 460-nm excitation, 510-nm emission, 5-nm slit 
width, and 0.5-s resolution for 2.5 min. The fluorescent data have 
been normalized to allow direct comparison. Transport assays were 
measured in triplicate.
Construction of SbmA mutants
Full-length sbmA (1-406) from E. coli K12 MG1655 was cloned into 
pBAD A Myc-His vector that carries a C-terminal His6-tag (Thermo 
Fisher Scientific) and expressed in strain JW0368-1 [F-, (araD- 
araB)567, lacZ4787(::rrnB-3), sbmA742::kan, -, rph-1, (rhaD-
rhaB)568, hsdR514] (a parent strain of Keio knockout collection). 
SbmA mutants were generated using the QuikChange Site-Directed 
Mutagenesis Kit (Agilent Technologies); DNA sequencing confirmed 
the presence of the mutations. To confirm that the WT protein and 
mutants express at similar levels during the growth inhibition assays, 
we estimated their expression by Western blot. The cells were incu-
bated in LB medium–supplemented kanamycin (50 g/ml) and 
ampicillin (100 g/ml); when the cultures reached an optical density 
(OD600) = 0.6, arabinose was added at the final concentration of 0.0002% 
and incubated at 37°C for further 2.5 hours. Membranes were isolated 
by breaking the cells with 0.1-mm glass beads. After ultracentrifugation, 
the pelleted membranes were resuspended in phosphate-buffered 
saline buffer, and the expression was confirmed by anti-His antibody 
Western blot. All proteins expressed at similar levels (fig. S13).
Growth inhibition assays
Growth curves were measured to analyze the ability of SbmA mu-
tants to transport bleomycin. Overnight cultures of E. coli strain 
JW0368 (sbmA::KmR) from the Keio collection transformed with 
expression plasmids for SbmA mutants were grown in LB medium 
supplemented with kanamycin (30 g/ml) and ampicillin (100 g/ml). 
The growth assay was carried out in 200-l volumes using sterile, 
flat-bottomed 96-well plates (Thermo Fisher Scientific). LB medium 
was supplemented with kanamycin (30 g/ml), ampicillin (100 g/ml), 
10 M l-arabinose, and 5 M bleomycin sulfate (Sigma-Aldrich) and 
inoculated with overnight culture in a ratio of 1:100. Control exper-
iments contained no bleomycin sulfate. Cells were grown at 37°C 
with shaking in a SpectraMAX190 (Molecular Devices) plate reader. 
The OD600 was measured every minute for 17 hours. Measurements 
were carried out in technical triplicates from three independent 
clones (biological replicas).
Spot-on-lawn assays
The activity of KLB, MccJ25, or MccB17 against strains expressing 
SbmA mutants was evaluated using a “spot on lawn” technique. M9 
[M9 salts with 1% glycerol and thiamine (10 g/ml)] or LB 1% agar 
was supplemented with ampicillin (100 g/ml) and 10 M arabi-
nose and prepared in 9-cm aseptic petri dishes (VWR). Overnight 
cultures of E. coli strain JW0368 (sbmA::KmR) transformed with 
expression plasmids for SbmA mutants, growing in an appropriate 
medium, were diluted in a ratio of 1:40 (adjusted according to the 
final culture OD, if necessary) in liquid 0.6% agar, which was over-
laid onto the M9 or LB agar plates. Two microliters of each inhibitor 
dilution (KLB, 500 M; MccB17 and MccJ25, 100 M) was spotted 
onto the surface of the seeded agar. Plates were incubated for 30 hours 
at 30°C (M9) or overnight at 37°C (LB).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.eabj5363
View/request a protocol for this paper from Bio-protocol.
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